Journals / Retina-Vitreus / 2009 / Cilt: 17 - Sayı: 4

Immunosuppression therapy in multifocal choroiditis and panuveitis

Multifokal koroidit ve panüveit’te immunosupresyon tedavisi

Pages
278–281
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

They have useful effects in visual prognosis and they decrease the ratio of development of CNVM.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the visual prognosis, ocular complications and the efficacy of the immunusuppressive drug treatment in the multifocal choroiditis and panuveitis (MFCP).
📊
Key Findings & Data:Materials and Methods: Twenty-seven eyes of 14 patients with MFCP who were admitted to the Uvea-Behçet Service between January 1997-January 2007 were included in this retrospective study.
💡
Conclusion & Impact:They have useful effects in visual prognosis and they decrease the ratio of development of CNVM.
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Koroidit · Floresan anjiyografi · İmmün baskılayıcı ajanlar

Abstract

Purpose: To evaluate the visual prognosis, ocular complications and the efficacy of the immunusuppressive drug treatment in the multifocal choroiditis and panuveitis (MFCP). Materials and Methods: Twenty-seven eyes of 14 patients with MFCP who were admitted to the Uvea-Behçet Service between January 1997-January 2007 were included in this retrospective study. Complete blood count, urine analysis, sedimantation rate, chest X-ray, and tests including syphilis, sarcoidosis, tuberculosis, brucellosis and toxoplasmosis were carried out. The visual acuity and intraocular pressure measurements, and biomicroscopic anterior segment, vitreous and fundus examinations were performed. Also fundus fluorecein angiography was obtained in some patients. Results: Age at the beginning of MFCP was 39.9±10.5 (25- 66), and ratio of male/female was ¾. The ocular involvement was bilateral in all patients. Mean follow-up period was 4.3±3.1 (1-11) years. While the mean best corrected visual acuity obtained from Snellen chart after conversion to logMar equivalent, at first admission was 0.58±0.63 (0.0-2.1), visual acuity at last visit during inactive phase of disease was 0.30±0.49 (0.0-2.1). Visual acuity at last visit was higher than the visual acuity at first admission (p=0.002). During the follow-up period 22 eyes (%81.5) had cystoid macular edema, 2 eyes (%7.4) choroidal neovascular membrane (CNVM), 15 eyes (%55.6) had glaucoma and 10 eyes (%37.0) had cataract. Eleven patients were given a combination therapy of oral corticosteroid, azatyoprine and cylosporine A. One patient received oral corticosteroid, azatyoprine and cylosporine A, and 2 patients received oral corticosteroid and cylosporine A. Conclusions: Immunusuppressive drugs suppress inflammmation adequately in MFCP patients. They have useful effects in visual prognosis and they decrease the ratio of development of CNVM.

Özet

Amaç: Multifokal koroidit ve panüveit (MFKP) hastalarında görsel prognoz, oküler komplikasyon ve immünosupresif ajanlarla tedavi etkinliğinin incelenmesi. Gereç ve Yöntem: Retrospektif olan bu çalışmaya Ocak 1997- Ocak 2007 yılları arasında kliniğimiz Uvea-Behçet bölümüne başvuran 14 MFKP’li hastanın 27 gözü dahil edilmiştir. Olguların tümünde tam kan, idrar, sedimentasyon, akciğer grafisi tetkikleri ile birlikte sifiliz, sarkoidoz, tüberküloz, brusella ve toksoplazmaya yönelik serolojik tester de uygulandı. Hastaların tümünde düzeltilmiş görme keskinlikleri ölçümü, göz içi basıncı ölçümü, biyomikroskopik ön segment ve vitreus muayenesi, fundus muayenesine ek olarak bir kısmında fundus floresein anjiografisi de yapıldı. Bulgular: Hastaların MFKP başlama ortalama yaşı 39.9±10.5 (25-66), kadın/erkek oranı ¾ idi. Göz tutulumu tüm hastalarda bilateral idi. Ortalama takip süresi 4.3±3.1 (1-11) yıldı. İlk başvurudaki Snellen eşelinde alınan ortalama düzeltilmiş görme keskinliği logMar birimine çevrildikten sonra 0.58±0.63 (0.0-2.1) iken hastalığın aktive olmadığı en son başvurudaki görme keskinliği 0.30±0.49 (0.0-2.1) idi. Son başvurudaki görme keskinliği ilk görme keskinliğine göre yüksek idi (p=0.002). Takip süresince 22 gözde (%81.5) kistoid makuler ödem (KMÖ), 2 gözde (%7.4) koroidal neovasküler membran (KNVM), 15 gözde (%55.6) glokom ve 10 gözde de (%37.0) katarakt tespit edildi. Onbir hastaya kombine olarak oral kortikosteroid, azatiyoprin ve siklosporin-A tedavisi uygulandı. Bir hasta oral kortikosteroid ve azatiyoprin tedavisi alırken, 2 hastada da oral kortikosteroid ve siklosporin-A tedavisi aldı. Sonuç: İmmunosupresif ilaçlar MFKP hastalarında yeterli oranda inflamasyonu baskılamaktadırlar. Ayrıca görsel prognoza olumlu etkileri olup KNVM gelişme oranını azaltmaktadırlar.

🔖

Cite This Article

SUNGUR, G., HAZIROLAN, D., KASIM, R., DUMAN, S. (2009). Immunosuppression therapy in multifocal choroiditis and panuveitis. Retina-Vitreus, Cilt: 17 - Sayı: 4, 278–281. https://ajindex.com/articles/307757

References (16)

  1. Nozik RA, Dorsch W.: A new chorioretinopathy associated with anterior uveitis. Am J Ophthalmol. 1973;76:758-762
  2. Dreyer RF, Gass JD.: Multifocal choroiditis and panuveitis: a syndrome that mimics ocular histoplasmosis. Arch Ophthalmol. 1984;102:1776-1784
  3. Deutsch TA, Tessler HH.: Inflammatory pseudohistoplasmosis. Ann Ophthalmol. 1985;17:461-465
  4. Joondeph BC, Tessler HH.: Clinical course of multifocal choroiditis: photographic and angiographic evidence of disease recurrence. Ann Ophthalmol. 1991;23:424-429
  5. Spaide RF, Yanuzzi LA, Freund KB.: Linear streaks in multifocal choroiditis and panuveitis. Retina. 1991;11:229-231
  6. Akbatur H.H., Akata F, Or M.: Multifokal koroidit ve panüveit. Ret-Vit. 1993;1:71-74
  7. Morgan C.M., Schatz H.: Recurrent multifocal choroiditis. Ophthalmology. 1986;93:1138-1147
  8. Brown J, Folk J.C., Reddy C.H., et al.: Visual prognosis of multifocal choroiditis and panuveitis, punctate iner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology. 1996; 103:1100-1105
  9. Michel SS, Ekong A, Baltatzis S, et al.: Multifocal choroiditis and panuveitis: immunomodulatory therapy. Ophthalmology. 2002;109:378-383
  10. Cantrill HL, Folk JC.: Multifocal choroiditis associated with progressive subretinal fibrosis. Am J Ophthalmol. 1986;101:170- 180
  11. Vianna RN, Ozdal PC, Filho JP, et al.: Longterm follow-up of patients with multifocal choroiditis and panuveitis. Acta Ophthalmol Scand. 2004;82:748-753
  12. Palestine AG, Nussenblatt RB, Parver LM, et al.: Progressive subretinal fibrosis and uveitis. Br J Ophthalmol. 1984;68:667-673
  13. Thorne JE, Wittenberg S, Jabs DA, et al.: Multifocal choroiditis with panuveitis: incidence of ocular complications and of loss of visual acuity. Ophthalmology. 2006;113:2310-2316
  14. Kedhar SR, Thorne JE, Wittenberg S, et al.: Multifocal choroiditis with panuveitis and punctate iner choroidopathy comparison of clinical characteristics at presentation. Retina. 2007;27:1174- 1179
  15. Nölle B, Faul S, Jenisch S, et al.: Peripheral multifocal choroiditis with panuveitis: clinical and immunogenetic characterization in older patients. Graefes Arch Clin Exp Ophthalmol. 1998; 236:451-460
  16. Dees C, Arnold JJ, Forrester JV, et al.: Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis. Arch Ophthalmol. 1998;116:1456-1461.